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The Cul4-DDB1-WDR3/WDR6 Complex Binds SPAK and OSR1 
Kinases in a Phosphorylation-Dependent Manner 
Binar A. Dhiani,[b] and Youcef Mehellou*[a] 
Abstract: SPAK and OSR1 are two protein kinases that play critical 
roles in regulating ion homeostasis. They are activated under osmotic 
stress via phosphorylation by their upstream WNK kinases at a 
conserved threonine site on their T-loops. Additionally, WNK kinases 
phosphorylate SPAK and OSR1 at a highly conserved serine residue 
on their S-motif, the function of which remains elusive. Using affinity 
pull down and mass spectrometry, we identified the E3 ubiquitin ligase 
complex Cullin 4-DDB1-WDR3/WDR6 as a binder to OSR1 kinase in 
a SPAK/OSR1 S-motif phosphorylation-dependent manner. This 
binding was found to be compromised by S-motif phosphorylation 
following osmotic stress. Using proteasomal and neddylation 
inhibitors, we subsequently showed the that OSR1 ubiquitylation was 
abolished under osmotic stress when its S-motif is phosphorylated. 
These results provide the first example of an E3 ubiquitin ligase 
system that binds the OSR1 kinase and, thus, links the CRL4 complex 
to ion homeostasis. 
The STE20/SPS1-related kinase (SPAK) and the Oxidative-
Stress-Responsive kinase 1 (OSR1) are two cytoplasmic 
serine/threonine protein kinases that phosphorylate a myriad of 
sodium, potassium and chloride ion co-transporters such as the 
sodium (Na), potassium (K) and chloride co-transporters 1 and 2 
(NKCC1 and NKCC2), the potassium (K) chloride (Cl) co-
transporters (KCCs) and the sodium (Na) and chloride (Cl) 
cotransporter (NCC) (Figure 1A).[1] Human SPAK and OSR1 
kinases are 68% identical in sequence and share a highly 
conserved 92-residue C-terminal domain (residues 456–547 for 
SPAK and 436–527 for OSR1), which are 79% identical in 
sequence.[2] Although under normal conditions these kinases are 
inactive, they become activated by osmotic stress.[3] 
At the molecular level, SPAK and OSR1 activation is mediated by 
T-loop phosphorylation at a highly conserved threonine residue
(T233 for SPAK and T185 for OSR1) by With No lysine kinases
(WNKs) (Figure 1A).[4] WNK kinases are a family of
serine/threonine protein kinases that are mutated in some
individuals with an inherited form of hypertension known as
Gordon’s syndrome.[5] Notably, WNK-phosphorylation of SPAK
and OSR1 kinases at their T-loops does not lead to their maximal
catalytic activity as for this to be achieved, they need to
subsequently bind a scaffolding protein known as Mouse Only
protein 25 (MO25).[6] In humans, there are two isoforms of MO25,
a and b,[7] and they both activate WNK-phosphorylated OSR1 and 
SPAK kinases to a similar level.[6]  
Beyond WNK-phosphorylation of SPAK and OSR1 at their T-
loops, WNK kinases also phosphorylate SPAK and OSR1 at their 
C-terminal domains.[4] Among the prominent C-terminal
phosphorylation sites on SPAK and OSR1 is the WNK-
phosphorylation of a highly conserved serine residue (S373 for
SPAK and S325 for OSR1) (Figure 1A and B). Although previous
studies showed that, unlike T-loop phosphorylation (A, Figure
1A), WNK-phosphorylation at S373 for SPAK and S325 for OSR1
does not affect their catalytic activities,[2, 4] the role of these
phosphorylation sites remained unknown. Herein, we show that
OSR1 binds the Cullin RING-E3 ubiquitin ligase complex Cul4-
DDB1-WDR3/WDR6 (CRL4) and its phosphorylation at S325 by
WNK kinases under osmotic stress compromises such binding.
Given our previous success with using biotinylated peptides and
pulldown assays in identifying proteins that bind SPAK and OSR1
kinases in a phosphorylation-dependent manner,[8] our pursuit of
understanding the function of OSR1 S325 phosphorylation by
WNK kinases started by synthesizing two N-terminally
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Figure 1. The WNK-SPAK/OSR1 signaling cascade. A. WNK kinases 
phosphorylate SPAK and OSR1 kinases at numerous sites including that in the 
T-loop and those in the S-motif (1-3). The function of these phosphorylation are 
well established apart from the S-motif phosphorylation (2). Once 
phosphorylated by WNK kinases, SPAK and OSR1 kinases phosphorylate a 
series of sodium, potassium and chloride ion co-transporters. Solid line arrows 
indicate phosphorylation. B. Sequence alignemnt of the human SPAK and 
OSR1 protein sequences showing the highly conserved region around the 
SPAK S373 and OSR1 S325 WNK phosphorylation sites (highlighted in 
yellow).  Sequence alignemnt was conducted using EMBL-EBI EMBOSS 
Matcher. 
biotinylated 19-mer peptides, which correspond to amino acids 
316-334 (KKVRRVPGSSGRLHKTEDG) of human OSR1, with
one of them having S325 phosphorylated and the other
unphosphorylated (Figure 2A). These peptides were
subsequently incubated with HEK293 cell lysates and then
underwent biotin-streptavidin pull down. As controls, we used an
N-terminally biotinylated 18-mer RFQV 
(SEEGKPQLVGRFQVTSSK), which is known to bind 
endogenous OSR1 and SPAK, and its corresponding single point 
mutant AFQV peptide (SEEGKPQLVGAFQVTSSK), which does 
not bind SPAK and OSR1.[2] The pulled down material underwent 
mass spectrometry analysis  to identify the proteins that bound to 
these peptides (Figure 2B). 
The results showed that the unphosphorylated OSR1 S325 
peptide pulled down the E3 RING ubiquitin ligases Cul4A and 
Cul4B as well as their known protein binder DNA damage-binding 
protein 1 (DDB1)[9] (Figure 2B). Intriguingly, the peptide with a 
phosphoserine corresponding to WNK-phosphorylation at OSR1 
S325 (and SPAK S373) did not show binding to Cul4 or DDB1. 
This suggested that Cul4 and DDB1 binding to OSR1 and SPAK 
kinases is affected by their WNK-phosphorylation at S325 and 
S373, respectively. As well as binding to DDB1, Cul4 is 
established to bind its substrates via DDB1-Cul4-associated 
factors (DCAF) proteins.[10] In our mass spectrometry data, two 
DCAF proteins, namely WD repeat-containing proteins (WDR) 3 
and 6, were identified (Figure 2B).  
In order to further confirm the binding, we subsequently repeated 
the pull-down assay from HEK293 cell lysates using the 
aforementioned peptides and employed Western blotting for the 
indicated proteins (Figure 2C). The results provided further 
evidence that the unphosphorylated OSR1-derived peptides 
bound to endogenous Cul4B and DDB1, while the binding to 
Cul4A was rather weak by Western blotting. Additionally, there 
was also binding observed to endogenous WDR3 and WDR6 
though the commercially available antibodies for these proteins 
were not very sensitive or clean. Notably, as observed in the mass 
spectrometry data (Figure 2B), the binding of these proteins to 
OSR1 occurred with the non-phosphorylated OSR1 S325 and not 
the phosphorylated one (Figure 2C).  
The most studied DCAF protein of CRL4 E3 Ubiquitin ligase is 
cereblon,[11] which binds the agent thalidomide and its analogues 
leading to the activation of Cul4 to degrade substrate proteins 
such as Aiolos.[12] To check if thalidomide and its analogues could 
lead to the degradation of SPAK and OSR1 kinases, we employed 
HEK293 cells, which express the CRL4 complex and Aiolos 
proteins. Treatment of HEK293 cells with thalidomide led to the 
degradation of Aiolos proteins as expected whereas no changes 
of SPAK and OSR1 total protein levels were observed 
(Supporting Figure S1).  This suggested that cereblon is not the 
DCAF protein that mediates the binding of OSR1 and SPAK 
kinases to the CRL4 complex, but rather WDR3 and WDR6 
proteins that were detected by the mass spectrometry and 
Western blotting (Figures 2B and C). 
Next, we studied whether the observed CRL4 complex binding to 
the OSR1-derived peptide could also occur with endogenous and 
overexpressed SPAK and OSR1. First, we overexpressed in 
HEK293 cells GST-tagged OSR1 with either Myc-tagged Cul4A 
or B, left the cell unstimulated or underwent treatment with 
hypotonic buffer to active WNK kinases that phosphorylate OSR1 
at S325 and SPAK at S373.[3] Following GST-pull down, the 
material underwent Western blotting for Myc and the results 
showed that both Myc-tagged Cul4A and B bound the full length 
GST-OSR1 though the binding was observed most under the 
untreated condition and to a lesser extent in cells where OSR1 
was phosphorylated at S325 because the treatment with the 
hypotonic buffer to activate WNK kinases (Figure 2D). Also, the 
overexpression of full-length GST-OSR1 with FLAG-tagged 
DDB1 in HEK293 cells that were either left unstimulated or treated 
with hypotonic buffer followed by pull down indicated that DDB1 
binds OSR1 when it is unphosphorylated at S325 (untreated), but 
not when phosphorylated (hypotonic) (Figure 2E). These 
observations are in line with the OSR1 S325-phosphorylation 
Figure 2. The CRL4 complex binds OSR1. A. Peptide sequences of the 
phosphorylated (pS325) or non-phosphorylated (S325) 19-mer OSR1 peptides 
(KKVRRVPGSSGRLHKTEDG) that were used in the pull down experiments. 
The peptides carry N-terminally biotin. B. Comassie stain of an SDS-PAGE gel 
showing the bands observed following the gel electropherosis of the material 
that was pulled down using the various peptides. The RFQV 
(SEEGKPQLVGRFQVTSSK) peptide, which binds SPAK and OSR1 , and its 
derivative AFQV (SEEGKPQLVGAFQVTSSK) peptide, which does not bind 
SPAK and OSR1, are derived from the human WNK4 kinase. They are also N-
terminaly biotinylated and they were used in this experiment as controls. The 
bands in squares correspond to the bands that showed noticable difference 
between pS325 and S325 peptides. All of the indicated bands were excised 
and analysed by mass spectrometry. The table lists the proteins that comprise 
the Cullin-RING ligase with Cul4 (CRL4) and had a Mascot Score ≥ 30. C. 
Western blotting verification of the binding of Cul4A/B, DDB1, and WDR3/6 to 
the phosphorylated and non-phosphorylated peptides following straptavidine-
biotin pulldown from HEK293 cell lysates. The RFQV and AFQV peptides were 
used as controls. D. Western blot verification of the binding of overexpressed 
full length FLAG-OSR1 to Myc-tagged full length Cul4A and B under untreated 
(U) or hypotonic (H) conditions [30 min treatment] after FLAG-pull down from 
HEK293 cells and immunoblotting for Myc. E. Western blot showing the binding 
of overexpressed GST-OSR1 full length to FLAG-DDB1 following GST-affinity 
pull down from HEK293 cells and immunobloting for FLAG. Prior to the pull
down, the cells were left unstimulated (U) or were treated with hypotonic buffer 
(H) for 30 min.
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Band No. Protein 
Name





1 SPAK 60 600 Q9UEW8
2 OSR1 58.2 89 O95747
5
(S325 -OSR1)
1 DDB1 128.1 261 Q16531
2 CUL4B 104.5 116 Q13620
3 WDR3 107.1 52 Q9UNX4
4 CUL4A 88.1 46 Q13619
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effect on its binding to Cul4A/B and DDB1 seen with the mass 
spectrometry and Western blotting data (Figure 2B and C, 
respectively). 
For binding at the endogenous level, SPAK and OSR1 kinases 
were immunoprecipitated from HEK293 cells, that were left 
untreated or treated with hypotonic buffer to activate WNK-
signaling. The immunoprecipitated material subsequently 
underwent Western blotting for DDB1 and WDR6 (Supporting 
Figure S2). The results showed that these proteins bound SPAK 
and  OSR1 at the endogenous level further supporting the findings 
shown in Figures 2B-E. Attempts at verifying SPAK and OSR1 
kinases binding to the Cul4A/B, and WDR3 at the endogenous 
level were limited by poor commercially available antibodies for 
these proteins. 
  To provide evidence the region where the CRL4 components 
bind OSR1, we conducted another pull down assay from HEK293 
cell lysate from cells that had been co-transfected with the  CRL4 
components and GST-OSR1 full length and its GST-tagged 
fragments (Figure 3A). These fragments were the kinase domain 
without the S-motif (1-311), kinase domain plus the S-motif (1-
363), OSR1 fragment without the C-terminal domain (1-435) and 
the C-terminal domain only (429-end) (Figure 3A). Following co-
transfection, the cells were left unstimulated or treated with 
hypotonic buffer. Upon cell lysis, the total cell lysates underwent 
Western blotting to check the protein expression (Supporting 
Figure S3). The cell lysates were then used in affinity pull down 
experiments followed by Western blotting. As shown in Figure 3, 
the full length human OSR1 bound to full length WDR3 and 6, 
which further confirms the previous results shown in Figure 2. 
Additionally, the binding of OSR1 to these proteins was more 
prominent in the untreated conditions than in the samples that had 
been treated with hypotonic buffer to phosphorylate the S-motif of 
the OSR1 by WNK kinases. In terms of the OSR1 fragments, the 
OSR1 kinase domain (1-311) showed binding to WDR3 and 6 that 
was more pronounced in the untreated samples as compared to 
the hypotonic ones. This was rather intriguing because this OSR1 
kinase fragment does not contain part of the OSR1 S-motif, yet 
binding to WDR3 and 6 was achieved (Figure 3B-C). This 
suggests that OSR1 binding to WDR3 and 6 proceeds via the 
kinase domain, but is further mediated by the S-motif. Given the 
large size of these proteins (> 100 kD), such notion may be 
possible. In terms of the other OSR1 fragments, WDR3 showed 
more consistent binding to OSR1 fragments that contained the S-
motif with S325 as expected (Figure 3B), whereas WDR6 binding 
to OSR1 1-363 and 1-435 was much weaker (Figure 3C). 
Notably, the OSR1 C-terminal domain (429-end), which lacks the 
kinase domain and S-motif, did not show any binding to WDR3 or 
6 (Figure 3B-C). In general, the results shown in Figure 3 support 
the earlier finding that WDR3 and 6 bind OSR1 through the S-
motif and the kinase domain.  
To get an insight into the function of the interaction between 
OSR1 and CRL4, we examined whether CRL4 ubiquitylates and 
degrades OSR1. For this, we co-expressed FLAG-OSR1 and HA-
tagged ubiquitin (HA-Ub) in HEK293 cells and treated the cells 
with a proteasome inhibitor MG132[13] and Nedd8 activator 
enzyme inhibitor MLN4924[14] under basal and hypotonic 
condition. Prior to the pull-down assays, the total cell lysate from 
each condition underwent Western blotting to confirm the 
expression levels of FLAG-OSR1 and HA-ubiquitin (Figure 4). 
Additionally, an immunoblot of Cullin 2 (Cul2) was also carried out 
as a read out of MLN4924 ability to inhibit neddylation. The results 
showed that in the samples treated with MLN4924, which is an 
inhibitor of RING E3 ubiquitin ligases, Cul2 appeared as a single 
band since the smaller upper band of Cul2, which corresponds to 
neddylated Cul2 (Cul2-Nedd), disappeared (Figure 4). This 
confirms the inhibition of neddylation in the samples that were 
treated with MLN4924. Furthermore, a Western blotting of the 
total cell lysate of each sample with HA antibody gave a significant 
signal in the samples treated with the MG-132 proteasome 
inhibitor. This inhibition was comparable in the untreated and 
hypotonic samples as expected since MG-132 inhibits the 
proteasomal degradation of all of the cell’s proteins.  
Subsequently, FLAG-tagged OSR1 was pulled down from each 
sample and the pulled down material was probed with an anti-HA 
antibody by Western blotting. The results gave strong HA-
ubiquitin signals only in the samples treated with the MG-132 
proteasomal degradation inhibitor as expected (Figure 4). 
Intriguingly, the data showed that OSR1 ubiquitylation was more 
pronounced in basal (untreated) condition compared to the 
hypotonic condition (Figure 4). This implied that ubiquitylation of 
OSR1 is reduced by the stimulation of WNK-signaling (hypotonic), 
which leads to its S-motif phosphorylation. This observation is in 
line with the earlier findings that the CRL4 complex binds OSR1 
under basal conditions and not under osmotic stress due OSR1 
phosphorylation on the S-motif. 
The fact that the Cul4-DDB1-WDR3/6 complex binds to SPAK 
and OSR1 kinases in resting conditions prior to osmotic stress-
induced phosphorylation by WNK kinases suggests that this 
ubiquitin ligase system may constitutively ubiquitylate SPAK and 
Figure 3. The CRL4 complex binds to the kinase domain of OSR1. A. 
Schematic diagram of the GST-OSR1 fragments that were used in pull down 
assays. B. GST-OSR1 and its fragments were co-expressed with His-WDR3 in 
HEK293 cells. Total protein lysate was prepared three days post-transfection 
and immunoblotting analysis was conducted after His pull down. Anti-GST 
antibody was used to detect the binding of OSR1 full length and its fragments 
to His-WDR3. C. As in C, using His-WDR6 and anti-GST antibodies. * indicates 
non-specific bands. In all cases, the cells were left unstimulated (U) or 



















































































































































































































OSR1 kinases under resting conditions, a physiological 
phenomenon that has been observed with other proteins.[15]  Such 
ubiquitylation is then inhibited under osmotic stress as a result of 
SPAK and OSR1 S-motif phosphorylation due to the loss of the 
Cul4-DDB1-WDR3/6 complex binding to SPAK and OSR1 
kinases following S-motif phosphorylation as indicated by the data 
presented herein. The type and function of such constitutive 
ubiquitylation needs to be further investigated. Notably, beyond 
the loss of the CRL4 complex binding to SPAK and OSR1, the S-
motif phosphorylation at other serine residues by WNK kinases, 
namely S387 for SPAK and S339 for OSR1 is known to mediate 
the binding of SPAK and OSR1 kinases to the scaffolding protein 
MO25.[8] This is now understood to be the second part of SPAK 
and OSR1 kinases activation as initially osmotic stress leads to 
SPAK and OSR1 phosphorylation on their T-loop by WNK 
kinases[4] and this is subsequently followed by binding to MO25, 
which leads to 80- to 100-fold increase in their kinase catalytic 
activity.[6] 
In conclusion, this work provides the first example of an E3 
ubiquitin ligase system that binds SPAK and OSR1 kinases. 
Critically, it provides a new molecular insight that links the CRL4 
complex to ion homeostasis and the regulation of blood pressure 
through SPAK and OSR1 kinases. Such notion is supported in 
some studies where deletion of Cul4A resulted in changed in 
blood pressure.[16]  This novel finding provides a new avenue for 
understanding the fundamental biology of ion homeostasis and 
the biology of diseases that involve salt imbalances and those 
where the CRL4 components are mutated. Critically, it highlights 
a potential new role for small molecule CRL4 binders as 
modulators of ion homeostasis. 
Experimental Section 
Full experimental details are provided in the Supporting Information. 
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Supporting Information 
I. MATERIALS
A. Reagents. The peptides used in this work were purchased from GL Biochem (China) and their sequences
were: RFQV (Biotin-C6-SEEGKPQLVGRFQVTSSK), AFQV (Biotin-C6- SEEGKPQLVGAFQVTSSK), S325-
OSR1 (Biotin-C6-KKVRRVPGSSGRLHKTEDG), pS325-OSR1 (Biotin-C6-KKVRRVPGSpSGRLHKTEDG).
Thalidomide (T144), DMEM (D6429), LB broth (L7275), LB agar (L7025) and ampicillin 100mg/mL (A5354),
Fetal Bovine Serum (F0804) and PenStrep (Gibco™ Penicillin-Streptomycin 10,000 (U/mL) were purchased
from Sigma-Aldrich (UK).
B. Antibodies. Anti-OSR1 (S636B), anti-SPAK (S551D and S637B) and anti-SPAK pS373 (S670B) were
purchased from the MRC PPU Reagents and Services, University of Dundee (UK). Anti-GAPDH rabbit mAb
(#2118), anti-SPAK (#2281), anti-CUL4A (#2699), anti-DDB1 (#5428), anti-HA (#3724), anti-Aiolos (#15103),
anti-Ubiquitin (#3933), anti-Myc HRP-conjugated (#14038), anti-DYKDDDDK (#14793), anti-rabbit IgG HRP-
linked antibody (#7074), anti-mouse IgG HRP-linked antibody (#7076) were purchased from Cell Signalling
Technology. Anti-CUL2 (ab166917), Anti-DDDDK (ab45766) and rabbit anti-Sheep IgG H&L HRP (ab97130)
were purchased from Abcam. Anti-CUL4B (C9995) was purchased from Sigma-Aldrich (UK). Anti-GST (8-
326) was purchased from Thermo Scientific, anti-WDR3 (102-1161) was purchased from RayBiotech, and
anti-WDR6 (PA5-41984) was purchased from Invitrogen.
C. Plasmids. Plasmid pEBG-GST-HA-OSR1 (DU44767), pCMV5-HA-Ubiquitin (DU3650), pCMV5-FLAG-
OSR1 (DU6194) and pEBG-GST empty were purchased from the MRC PPU Reagents and Services,
University of Dundee (UK).  pEBG-GST-HA-OSR1 containing GST-HA-OSR1 insert in pEBG6P as parent
plasmid. pCMV5-HA-Ubiquitin expressing HA-Ub from pCMV5 as parent plasmid which was inserted by HA-
Ub in BamHI restriction site as N-terminal insert for mammalian expression. pCMV5-FLAG-OSR1 containing
FLAG-OSR1 was inserted in parental plasmid pCMV5-FLAG1. The plasmids of pcDNA3-Myc3-Cul4A
(#19951), pcDNA3-Myc3-Cul4B (#19922), pcDNA3-FLAG-DDB1 (#19918), and pcDNA5-FRT/TO-Venus-
Flag (#40998) as FLAG empty vector were purchased from Addgene. The gene of interests in all the plasmids
were inserted in N-terminal of the parental plasmid. Myc3-Cul4A was inserted in pcDNA3 EcoRI (5’) and ApaI
(3’) cloning site. pcDNA3-Myc3-CUL4B with CMV as promoter was inserted in pcDNA3-Myc3 as vector
backbone. The FLAG-DDB1 insert in pcDNA3 as parent plasmid also used CMV as promoter. The plasmids
of pcDNA5D-FRT-TO-6xHis-WDR3 (DU63480) and pcDNA5D-FRT-TO-6xHis-WDR6 (DU63606) were
purchased from the MRC PPU Reagents and Services, University of Dundee (UK). Both plasmids were
inserted in BamHI restriction site for mammalian expression.  The plasmids for the fragments of GST-HA-
OSR1 (pEBG6P GST-HA-OSR1 1-311 (DU6018), pEBG6P-GST-HA-OSR1 1-363 (DU6019), pEBG6P-GST-
HA-OSR1 1-435 (DU6020) and pEBG6P-GST-HA OSR1 429-end (DU6586) were also obtained from the
MRC PPU Reagents and Services, University of Dundee (UK). The GST-HA was inserted as N-terminal of
OSR1 in BamHI restriction site of pEBG6P parental plasmids for mammalian expression.
II. METHODS
A. Cell culture. HEK293 cells were cultured in DMEM (D6429, Sigma) supplemented with 10% Fetal Bovine
Serum (FBS) and 1% of PenStrep. HEK293 cells were maintained in T75 flasks at 37°C and 5% CO2.
Subculturing was done when the cells reach 80-90% confluency. Hypotonic condition was applied to stimulate
WNK signalling by replacing media with hypotonic low Cl-  buffer pH 7.4 (67.5 mM sodium gluconate, 2.5 mM
potassium gluconate, 0.5 mM CaCl2/MgCl2, 1mM Na2HPO4/Na2SO4 and 7.5 mM HEPES) [1] for 30 minutes
incubation at 37 °C, and under 5% CO2.
B. Preparation of total protein lysate and protein concentration measurement. The cells were lysed
when they were at 70-80% confluency. The cells were first washed with Phosphate Buffer Saline (PBS)
(D8662, Sigma) and then 300-400 µL lysis buffer (50 mM Tris-HCl pH 7.5, 1 mM EDTA, 1 mM EGTA, 0.3%
CHAPS, 0.27 M sucrose, 1 mM Na3VO4, 50 mM NaF, 5 mM sodium pyrophosphate, 1 mM benzamidine and
0.1 mM PMSF) was used to each 10 cm dish. The cells were scrapped, and the lysates were transferred to
microtubes and spun down at 10,000 rpm for 10 minutes at 4 °C. Finally, the supernatant was transferred to
new microtubes and stored at -20°C. Protein concentration was measured using Bradford Assay[2]. 0.125;
0.25; 0.5 and 1 mg/ml of Bovine Serum Albumin (BSA) was used as protein standard in the Bradford assay.
C. Peptide Pull Down. Streptavidin sepharose high performance beads (GE Healthcare), pre-washed with
buffer A (10 mM Tris-HCl (pH 8), 0.1 mM EGTA), were incubated with 1 mg of HEK293 total protein lysate at
4 °C for 10 min and then washed with buffer A as a pre-clearing step. This was carried out three times. Upon
the third wash with buffer A, the pre-cleared supernatant was incubated on ice with 3 µg of the relevant peptide
for 10 min. 20 µL streptavidin beads, which had been pre-washed with buffer A, were then added to the
HEK293 protein lysate/peptide mixture and incubated for 5 min at 4 °C in rolling shaker. Finally, the beads 
were washed twice with CHAPS lysis buffer and twice with buffer A. 
D. Immunoprecipitation. Anti-SPAK or anti-OSR1 antibodies were conjugated to protein G-sepharose beads
(PC-G5, Generon) via the covalent cross-linking method using dimethyl pimelimidate (D8388, Sigma-Aldrich)
with ratio 1:1.[3] Prior to the immunoprecipitation, HEK293 total protein lysates were pre-cleared by incubation
with protein G-sepharose beads at 4 °C for 10 min and washed with buffer A. This pre-clearing step was
carried out three times. 1 mg of pre-cleared lysates were then incubated overnight in rolling shaker at 4 °C
with 20 µL of anti-SPAK or anti-OSR1 antibody-protein G-sepharose bead conjugates. Next, the beads were
washed twice with CHAPS lysis buffer and twice with buffer A. The collected beads were then prepared for
SDS PAGE, at a final concentration of 1 µg/ µL, by adding 1x SDS loading buffer and boiling 95 °C for 5
minutes.
E. GST Pull Down. 40 µL of GST beads (Glutathione Sepharose High Performance, GE Healthcare) were
first washed with 1 mL PBS or buffer A three times. Once washed, the GST beads were incubated at 4 °C
overnight with 1 mg HEK293 total protein lysates that overexpress the GST tagged protein of interest. The
beads then were collected by centrifugation 500 rpm, 1 min at 4 °C. Subsequently, 1 mL of CHAPS lysis
buffer and Buffer A were used to wash the beads (twice with each buffer). Finally, 100-150 µL of 1x SDS
loading buffer was added to the beads, gently mixed and boiled at 95°C for 5 minutes.
F. FLAG Pull Down. The resin beads (Anti-FLAG M2 affinity gel, Sigma Aldrich UK) were washed with TBS
buffer (50 mM Tris-HCl, 150 mM NaCl pH7.4, 0.1 M glycine pH 3.5) three times. 40 µL of FLAG beads were
then equilibrated with TBS buffer before being incubated 1 mg total protein lysate overnight at 4 °C. Following
centrifugation, the FLAG beads were washed three times with TBS buffer and 1x SDS loading buffer was
added. The suspension was then boiled for 95 °C for 5 and used in immunoblotting studies.
G. His Pull Down. His pull down was performed using HisPur Ni-NTA resin bead (Thermo Scientific). 1 mg
of HEK293 total protein lysate was incubated with 500 µL of binding buffer (20 mM Tris-HCl pH8.0, 100 mM
NaCl, 30 mM Imidazole and 10 µg/ml BSA) and 20 µL Ni-NTA resin bead at 4°C overnight. The beads were
then pelleted by centrifugation, 700 rpm for 1 minute, and washed three times with the washing buffer (20
mM Tris-HCl pH8.0, 200 mM NaCl, 50 mM imidazole and 0.2% Tween-20). 100 µL of 1xSDS loading buffer
was then added to the beads and the suspension was boiled (95 °C) and 5 minutes before being used in the
immunoblotting studies.
H. Immunoblotting. 15-20 µg of total protein was loaded per well, and these were subjected to separation in
polyacrylamide gels containing 1% SDS and transfer onto nitrocellulose membrane. The membranes were
blocked in 10% skimmed milk in TBST (50 mM Tris/HCl (pH 7.5), 0.15 M NaCl containing 0.25% Tween-20)
for 30 minutes at room temperature. The membranes were then incubated with the respective primary
antibodies in 5% BSA or 5% skimmed milk in TBST overnight at 4 °C or 1 hour at room temperature. Following
the washing of the membranes with TBST (five times, 5 minutes per wash), the membranes were then
incubated with the respective secondary antibodies for 1 hour at room temperature. Following the final wash
of the membranes with TBST (five times, 5 minutes per wash), protein detection on the membranes was
performed using horseradish peroxidise-conjugated secondary antibodies and the ECL® reagent (Amersham
Bioscience).
I. Protein overexpression and co-overexpression. Transformation of all cDNA plasmids to E.coli DH5α
(Invitrogen) was done by heat shock at 42 °C for 90 seconds. The mixture was then spread on LB agar plate
supplemented with 100 µg/µL ampicillin and incubated at 37 °C overnight. The grown colonies were grown in
500 mL LB media supplemented with ampicillin (100 µg/µL) at 37 °C overnight with 180 rpm shaking to
increase the copy number of recombinant DNA. Plasmid DNA extraction from the overnight cultures was
performed using Qiagen Plasmid Maxi Kit (Cat. No.12163) following the company’s kit protocols. The DNA
concentration was determined using PHERAstar FS (BMG Labtech) and NanoVue Plus (GE Healthcare
Lifesciences) was used to determine the quality of the isolated DNA. Finally, cDNA plasmids were transiently
transfected or co-transfected in HEK293 cells using polyethylenimine (PEI) (Sigma-Aldrich) in serum and free
antibiotic growth media. Transfected cells were then lysed 2-4 days post-transfection. The lysates from each
experiment underwent pulldown experiments as described above.
J. Mass Spectrophotometry analysis for protein identification. After protein separation by SDS-PAGE
and gel staining using NOVEX Colloidal Blue Staining Kit (LC6025, Invitrogen), the gel bands of interest were
excised. The gel slices were then washed and lysed with trypsin before mass spectrophotometry (MS)
analysis using previously reported protocols.[4]
K. MLN4924 and MG132 treatment on HEK293 cell. HEK293 cells were ca. 80% confluent when they were
treated with MLN4924 (Biovision) and MG132 (LKT Laboratories). These compounds were initially prepared
in 100 mM stock solutions in DMSO. The compounds were then further diluted down, in DMSO, and used to
treat the cells with MLN4924 (1 µM for 6 h), MG-132 (10 µM for 24 h) and a final concentration of DMSO not 
exceeding 0.1%.  
L. HEK293 cells treatment with thalidomide. The cells were cultured in 6-well plates before treatment with
the compounds. Thalidomide was prepared in 100 mM stock solution in DMSO. To achieve the final
concentrations of the compound, serial dilution of stock solution was prepared so that the highest
concentration of DMSO in the cells was 0.1%.
III. SUPPORTING FIGURES
Figure S1. Cereblon (CRBN) is not the substrate adaptor of CRL4 complex which binds to OSR1. HEK293 
cells were treated with thalidomide at the indicated concentrations and incubation times. Following lysis, the cell 
lysates underwent Western blotting for total endogenous SPAK and OSR1 kinases as well as the CRL4 substrate 
Aiolos. 20 ug of total protein was loaded in each sample. GAPDH was used as a loading control. The total levels 
of SPAK and OSR1 remained the same under all the thalidomide conditions while those of Aiolos, as expected, 
were reduced in a dose-dependent manner.  
Figure S2. A Western blot showing the binding of various endogenous CRL4 complex proteins to endogenous 
SPAK and OSR1 following their immunoprecipitation from HEK293 cells. A. HEK293 cells were either left 
unstimulated (U) or treated with hypotonic low-chloride buffer (H) and then lysed. 3 mg of total protein cell lysate 
was incubated with anti-SPAK conjugated beads overnight to immunoprecipitate endogenous SPAK. Following the 
washing of the beads, the material left on the beads was treated with SDS sample buffer, and underwent Western 
blotting for DDB1 and WDR6 antibodies. B. As in A., but immunoprecipitation was performed using Anti-OSR1 
conjugated beads. 
Figure S3. A Western blot showing the overexpression in HEK293 of GST-OSR1 full-length (FL) or its fragments 
with A. His-WDR3 and B. His-WDR6. Following the overexpression of the indicated proteins in HEK293 cells, the 
cells were lysed and immunoblotting for GST was performed and shown in this figure.  
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